Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Results TNF-α was a key determinant for B10 cells. TNF-α elicited the proinflammatory feature of B10 and B10pro cells by downregulating IL-10, and upregulating interferon-γ and IL-17A. In patients ...

Objective Although low infliximab trough concentrations and antibodies to infliximab ... inflammation in these individuals may be driven by processes that are not TNF dependent. Accordingly, a switch ...

Anti-Tumor Necrosis Factor (aTNF) biological therapies, such as infliximab, adalimumab and etanercept, are effective in treating Rheumatoid Arthritis (RA), Spondyloarthritis (SpA), Psoriasis (Ps) and ...

kuleuven.be With great interest, we read the report of Lu et al on the influence of proton pomp inhibitor (PPI) therapy on the outcome of infliximab therapy in ... drugs on the outcome of anti-tumor ...

The rate of TB was higher for adalimumab and infliximab than etanercept. During the first 6 years of therapy, no overall elevation of cancer risk was seen with any of the three TNF-antagonists.

It’s been a minute since Lifehacker looked at the slang of Generation Z—long enough that Generation Alpha has had time to develop and spread some of its own special buzzwords and jargon.

Key Preclinical Data Highlights SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human ...

Tumor necrosis factor alpha (TNF α) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles ...

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells in vitro, but its physiological role in tumor surveillance remains unknown. Here ...

today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple ...